Vistagen reports positive preliminary data from Phase 3 social anxiety disorder trial

Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read

Key Changes

• high

  Preliminary positive data announced from PALISADE-3 Phase 3 open-label extension study evaluating fasedienol for acute treatment of social anxiety disorder, marking progress in the company's lead drug development program.

  Item 8.01 verify on EDGAR →
• high

  Results are from the ongoing open-label extension portion of the trial, which follows the controlled phase and provides additional safety and efficacy data over a longer treatment period.

  Press Release verify on EDGAR →